[Enfortumab vedotin (urothelial cancer, first line treatment, combination with pembrolizumab) – addendum to Project A24-98]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018013998
German
Original Title:
Enfortumab Vedotin (Urothelkarzinom, Erstlinientherapie, Kombination mit Pembrolizumab)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a25-22.html
Year Published:
2025
URL for published report:
https://www.iqwig.de/download/a25-22_enfortumab-vedotin_addendum-zum-projekt-a24-98_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Urologic Neoplasms
- Carcinoma, Transitional Cell
- Antibodies, Monoclonal
- Antineoplastic Agents, Immunological
Keywords
- Enfortumab Vedotin
- Urologic Neoplasms
- Carcinoma – Transitional Cell
- Benefit Assessment
- NCT04223856
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.